Opaganib
Opaganib
Opaganib (pronounced: oh-pa-ga-nib) is an experimental drug currently being researched for its potential use in the treatment of various diseases, including COVID-19 and cancer.
Etymology
The term "Opaganib" is a coined name for the drug, which is also known by its chemical name, Yeliva (ABC294640). The name does not have a known etymology as it is a proprietary name given by the drug's developer, RedHill Biopharma.
Usage
Opaganib is an orally-administered, selective sphingosine kinase-2 (SK2) inhibitor. SK2 is an enzyme that plays a key role in the synthesis of sphingolipids, a class of lipids that have been implicated in various pathological processes, including inflammation and cancer. By inhibiting SK2, Opaganib is thought to exert anti-inflammatory and anti-cancer effects.
In the context of COVID-19, Opaganib is being investigated for its potential to reduce the severe inflammation associated with the disease. In cancer, it is being studied for its potential to inhibit the growth and spread of cancer cells.
Related Terms
- RedHill Biopharma: The pharmaceutical company that is developing Opaganib.
- Sphingosine kinase-2 (SK2): The enzyme that Opaganib targets.
- Sphingolipids: A class of lipids that are targeted by Opaganib.
- COVID-19: A disease for which Opaganib is being researched as a potential treatment.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells, for which Opaganib is being researched as a potential treatment.
External links
- Medical encyclopedia article on Opaganib
- Wikipedia's article - Opaganib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski